Israël - hébreu - Ministry of Health

inovamed ltd - ondansetron as hydrochloride dihydrate 2 mg / 1 ml - solution for injection - ondansetron - adults:ondansetron inovamed is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. ondansetron inovamed is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv). paediatric population:ondansetron inovamed is indicated for the management of chemotherapy-induced nausea and vomiting (cinv) in children aged ?6 months, and for the prevention and treatment of ponv in children aged ?2 years.

Israël - hébreu - Ministry of Health

novartis israel ltd - capmatinib as dihydrochloride monohydrate - טבליות מצופות פילם - capmatinib as dihydrochloride monohydrate 150 mg - capmatinib

Israël - hébreu - Ministry of Health

novartis israel ltd - capmatinib as dihydrochloride monohydrate - טבליות מצופות פילם - capmatinib as dihydrochloride monohydrate 200 mg - capmatinib

Israël - hébreu - Ministry of Health

perrigo israel pharmaceuticals ltd - granisetron as hydrochloride - solution for injection - granisetron - for the treatment of nausea and vomiting associated with antineoplastic therapy.

Israël - hébreu - Ministry of Health

teva pharmaceutical indust.ltd - granisetron as hydrochloride 3 mg / 3 ml - solution for infusion - granisetron - for the prevention and control of nausea and vomiting induced by cytostatic therapy (chemotherapy and radiotherapy).

Israël - hébreu - Ministry of Health

padagis israel agencies ltd, israel - alfuzosin hydrochloride - טבליות בשחרור ממושך - alfuzosin hydrochloride 10 mg - alfuzosin - alfuzosin - treatment of certain functional symptoms of benign prostatic hypertrophy, particularly if surgery has to be delayed for some reason.

Israël - hébreu - Ministry of Health

merck serono ltd - tepotinib as hydrochloride hydrate - טבליות מצופות פילם - tepotinib as hydrochloride hydrate 225 mg - tepotinib

Israël - hébreu - Ministry of Health

j-c health care ltd - decitabine - אבקה להכנת תמיסה מרוכזת לעירוי - decitabine 50 mg/vial - decitabine - decitabine - - dacogen is indicated for treatment of patients with myelodysplastic syndromes (mds) including prevviously treated and untreated, de novo and secondary mds of all french-american- british subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia ) and intermediate- 1, intermediate- 2, and high-risk international prognostic scoring system groups.- dacogen is indicated for the treatment of adult patients aged 65 years and above with newly diagnosed de novo or secondary acute myeloid leukaemia (aml), according to the world health organisation (who) classification, who are not candidates for standard induction chemotherapy

Israël - hébreu - Ministry of Health

perrigo israel agencies ltd - vinflunine ditartrate - תרכיז להכנת תמיסה לאינפוזיה - vinflunine ditartrate 25 mg/ml - vinflunine - vinflunine - javlor is indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinium-containing regimen. efficacy and safety of vinflunine have not been studied in patients with performance status ?2.

Israël - hébreu - Ministry of Health

medici ltd - bcg 81 mg/vial - powder for reconstitution - bcg vaccine - for the treatment of superficial transitional cell carcinoma (tcc) of the urinary bladder, regardless of antecedent intravesical treatment superficial tcc comprises the following: carcinoma in situ (cis), papillary tumors limited to the mucosa (stage ta), papillary tumors invoiving the lamina propria but not the muscle layer of the bladder (stage t1), or any combination thereof. immucyst is indicated for treatment and prophylaxis of primary or recurrent carcinoma insitu (cis) of the urinary bladder and for prophylaxis following trans-urethral resection (tur) of primary or recurrent stage ta and/or t1 papilary tumors.